We are live on ! Find out more
TLSI icon

TriSalus Life Sciences
TLSI

9 hedge funds and large institutions have $17.3M invested in TriSalus Life Sciences in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 64 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

86.76% less ownership

Funds ownership: 93.64% → 6.88% (-87%)

88% less funds holding

Funds holding: 72 → 9 (-63)

92% less capital invested

Capital invested by funds: $225M → $17.3M (-$207M)

98% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 64

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
9
Holders Change
-63
Holders Change %
-87.5%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
1
Reduced
3
Closed
64
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$124K
2
UBS Group
UBS Group
Switzerland
+$20.4K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$27.1M
2
DM
Deerfield Management
New York
-$9.93M
3
GCL
Glazer Capital LLC
New York
-$9.56M
4
Marshall Wace
Marshall Wace
United Kingdom
-$7.9M
5
HSBC Holdings
HSBC Holdings
United Kingdom
-$7.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
MF
1
Magnetar Financial
Illinois
$11.5M -$1.35M -135,119 -11%
DFCM
2
Dark Forest Capital Management
Puerto Rico
$3.5M – – –
SIA
3
SkyView Investment Advisors
New Jersey
$1.5M – – –
MC
4
Meteora Capital
Florida
$241K -$274K -27,335 -53%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$173K – – –
BFM
6
Boothbay Fund Management
New York
$160K -$1.92M -191,367 -92%
VF
7
Virtu Financial
New York
$124K +$124K +12,320 New
Morgan Stanley
8
Morgan Stanley
New York
$40.6K – – –
UBS Group
9
UBS Group
Switzerland
$20.7K +$20.4K +2,037 +9,259%
BlackRock
10
BlackRock
New York
– -$27.1M -2,728,633 Closed
DM
11
Deerfield Management
New York
– -$9.93M -999,999 Closed
GCL
12
Glazer Capital LLC
New York
– -$9.56M -963,032 Closed
Marshall Wace
13
Marshall Wace
United Kingdom
– -$7.9M -795,519 Closed
Bank of Montreal
14
Bank of Montreal
Ontario, Canada
– -$7.78K -781,803 Closed
HSBC Holdings
15
HSBC Holdings
United Kingdom
– -$7.25M -730,322 Closed
FTCM
16
First Trust Capital Management
Illinois
– -$7.08M -713,532 Closed
Bank of America
17
Bank of America
North Carolina
– -$6.95M -700,000 Closed
RL
18
RPO LLC
Connecticut
– -$6.95M -699,600 Closed
Jane Street
19
Jane Street
New York
– -$6.53M -657,389 Closed
Verition Fund Management
20
Verition Fund Management
Connecticut
– -$6.07M -611,128 Closed
UOC
21
UBS O'Connor
Illinois
– -$5.48M -551,483 Closed
IPCP
22
Iron Park Capital Partners
New York
– -$5.46M -550,000 Closed
KC
23
Kryger Capital
United Kingdom
– -$5.12M -515,555 Closed
KL
24
KIM LLC
Kansas
– -$5M -503,600 Closed
RCM
25
Radcliffe Capital Management
Pennsylvania
– -$4.63M -466,487 Closed
1
2 3

TLSI Hedge Fund Activity: Q4 2022 in Review

9 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q4 2022, worth a combined $17.3M — down 92% from $225M a quarter earlier.

Sellers outnumbered buyers: 64 funds closed out of TLSI and 1 opened new positions — a net loss of 63 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was Virtu Financial, opening a new position worth an estimated $124K. The largest seller was BlackRock, exiting entirely with an estimated $27.1M sold.

  • 9 institutional investors held TriSalus Life Sciences (TLSI) as of Q4 2022, down from 72 in Q3 2022.
  • Funds reported $17.3M of TriSalus Life Sciences stock for Q4 2022, down 92% quarter-over-quarter.
  • 1 fund opened new TriSalus Life Sciences positions in Q4 2022 and 64 closed out, a net change of -63 holders.
  • The largest TriSalus Life Sciences buyer in Q4 2022 was Virtu Financial, an estimated $124K added.
  • The largest TriSalus Life Sciences seller in Q4 2022 was BlackRock, an estimated $27.1M sold.

Based on aggregated 13F filings for Q4 2022.